SCIT vs SLIT: What Is the Difference?

Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are two ways of treating certain allergies by gradually exposing the immune system to carefully selected allergens. Unlike antihistamines, nasal sprays, and other medications that primarily control symptoms, allergen immunotherapy is designed to reduce the immune system’s sensitivity to specific allergy triggers over time.

The main difference between SCIT and SLIT is how the allergen is administered. SCIT is given as an injection under the skin, usually in a medical office. SLIT is placed under the tongue as a tablet or liquid preparation and is generally taken at home after appropriate medical evaluation and instruction.

However, the differences go beyond needles versus drops. SCIT and SLIT may vary in allergen coverage, treatment schedule, supervision requirements, side effects, regulatory status, cost, and suitability for individual patients.

Patients and healthcare professionals exploring personalized treatment can review available allergy immunotherapy options and discuss the appropriate route with a licensed prescriber.

SCIT vs. SLIT at a Glance

Feature	SCIT	SLIT
Full name	Subcutaneous immunotherapy	Sublingual immunotherapy
Administration	Injection under the skin	Tablet or liquid placed under the tongue
Typical location	Medical office or clinic	Usually at home after medical instruction
Frequency	Frequent visits during build-up, followed by maintenance injections	Usually taken daily
Common uses	Environmental allergens and, in specialized protocols, insect venom	Selected environmental allergens; some specialist-directed, off-label programs may involve other allergens
Allergen flexibility	Can often include several clinically relevant environmental allergens	FDA-approved tablets target specific allergens; liquid formulations vary by prescription
Common local side effects	Redness, itching, or swelling at the injection site	Itching, tingling, or mild swelling in the mouth or throat
Systemic reaction risk	Uncommon but potentially serious; office observation is required	Generally lower than SCIT, but serious reactions remain possible
Needle-free	No	Yes
FDA status in the United States	Injectable allergen extracts are licensed for diagnostic and therapeutic uses	Certain tablets are FDA-approved; liquid allergy drops are not FDA-approved
Adherence challenge	Attending repeated clinic appointments	Remembering to take the treatment consistently at home

What Is SCIT?

SCIT stands for subcutaneous immunotherapy. It is commonly known as allergy shots.

During SCIT, measured amounts of the relevant allergens are injected into the tissue beneath the skin, usually in the upper arm. The dose is gradually increased during a build-up period until the patient reaches an individualized maintenance dose.

According to the American Academy of Allergy, Asthma & Immunology, a typical conventional build-up schedule may involve injections approximately once or twice per week for three to six months. Maintenance injections are then commonly spaced two to four weeks apart. Successful treatment is often continued for three to five years, although the schedule must be individualized by the treating allergist.

How Does SCIT Work?

SCIT repeatedly introduces controlled amounts of an allergen to the immune system. Over time, this may promote immunologic tolerance and reduce the exaggerated immune response that causes symptoms such as:

• Sneezing
• Nasal congestion
• Runny nose
• Itchy or watery eyes
• Allergy-related coughing or wheezing
• Reactions to certain stinging insects

The treatment does not simply block histamine for a few hours. Its purpose is to modify the patient’s response to the allergen over an extended period.

What Allergies Can SCIT Treat?

Depending on the patient’s test results and clinical history, SCIT may be considered for allergies involving:

• Grass, tree, and weed pollens
• House dust mites
• Animal dander
• Mold spores
• Cockroach allergens
• Bee, wasp, hornet, or other insect venom

SCIT is not routinely used to treat food allergies. Injectable food allergen extracts in the United States are intended for diagnostic use rather than food-allergy immunotherapy.

What Are the Benefits of SCIT?

One of SCIT’s main advantages is flexibility. A clinician may be able to formulate treatment around several clinically relevant environmental allergens identified through testing and symptom history.

SCIT also has a long history of use and a substantial evidence base. For appropriately selected patients, it may:

• Reduce allergy symptoms
• Decrease the need for symptom-relief medications
• Improve quality of life
• Provide benefits that may continue after treatment is discontinued
• Treat several relevant environmental allergens within one supervised program

SCIT may be particularly useful when a patient has multiple environmental sensitivities or when the allergist wants precise control over dose escalation.

What Is SLIT?

SLIT stands for sublingual immunotherapy. “Sublingual” means that the treatment is administered under the tongue.

SLIT may be provided as a tablet or a liquid preparation. The allergen is held under the tongue according to the prescribed directions. After the initial evaluation, education, and any required supervised first dose, treatment is generally taken at home.

Daily administration makes SLIT more convenient for many patients, especially those who cannot regularly travel to a clinic or who prefer to avoid injections.

SLIT Tablets vs. SLIT Drops

It is important not to treat all forms of SLIT as though they have the same regulatory status.

In the United States, the FDA has approved specific sublingual tablets for certain grass pollens, ragweed pollen, and house dust mites. The FDA’s current list includes GRASTEK, ORALAIR, ODACTRA, and RAGWITEK. Each product is designed for a defined allergen and must be used according to its prescribing information.

Liquid SLIT drops are different. Customized liquid allergy drops are not FDA-approved products in the United States. They may be prescribed and compounded for an individual patient under a licensed clinician’s direction, but their use is considered off-label. Professional organizations emphasize that evidence, dosing, and formulation may vary among liquid SLIT programs.

AccuMix compounds patient-specific SLIT drops after receiving a valid prescription. Its website also states that compounded immunotherapy preparations are made from allergen extracts sourced from FDA-licensed manufacturers but are not themselves reviewed or approved by the FDA.

What Allergies Can SLIT Treat?

FDA-approved SLIT tablets are available for defined allergens, including:

• House dust mites
• Ragweed pollen
• Timothy grass and related grasses
• A five-grass pollen mixture

Liquid SLIT programs may be customized by a prescriber for other airborne allergens. However, the evidence and standardization for compounded drops should not be assumed to be identical to those of FDA-approved tablets.

SLIT has also been investigated for certain food allergies. These applications are distinct from standard treatment for environmental allergic rhinitis and should only be considered within a qualified specialist’s protocol. Patients should not use environmental allergy drops to self-treat food allergies.

The Main Differences Between SCIT and SLIT

1. Route of Administration

SCIT is injected beneath the skin. SLIT is placed under the tongue.

For patients with a significant fear of needles, SLIT may be easier to accept. For others, receiving treatment in a supervised clinic may provide greater confidence and accountability.

2. Treatment Location

SCIT injections are administered in a medical setting equipped to recognize and treat allergic reactions. Patients are commonly asked to remain in the clinic for at least 30 minutes after an injection because most serious injection-related reactions occur during this period.

SLIT is usually taken at home after the patient receives instructions from the prescriber. Depending on the product or clinical protocol, the first dose may be administered under medical supervision.

3. Frequency and Schedule

SCIT normally has two stages:

Build-up phase: Increasing doses are administered through frequent clinic visits.

Maintenance phase: Once the effective dose has been reached, injections are given less frequently.

SLIT is generally taken daily. This removes the need for frequent office visits, but it transfers more responsibility to the patient. Missing repeated doses may reduce the effectiveness of treatment or require instructions from the prescriber before restarting.

4. Allergen Coverage

SCIT often offers broader flexibility for patients with several clinically important environmental allergies. The injection mixture may be selected according to the patient’s testing, exposure, symptoms, and the compatibility of the extracts.

FDA-approved SLIT tablets target specific allergens rather than broad combinations. Customized liquid SLIT preparations may include different allergens, but their dosing and evidence base differ from those of approved tablets.

Therefore, SLIT should not automatically be considered interchangeable with SCIT simply because both use allergen extracts.

5. Effectiveness

Both SCIT and SLIT can reduce symptoms and medication use in appropriately selected patients with inhalant allergies.

It is difficult to declare one route universally more effective because studies use different allergens, formulations, doses, age groups, treatment durations, and outcome measures. Reviews comparing the two have often found that the available head-to-head evidence is insufficient to establish a clear overall winner. Some studies favor SCIT for particular outcomes, while others find comparable results or advantages for SLIT in selected populations.

The most important question is not simply, “Which treatment is stronger?” It is, “Which evidence-based treatment matches this patient’s allergens, medical history, risks, lifestyle, and ability to follow the schedule?”

6. Safety

Both forms of immunotherapy expose the patient to an allergen, so neither option is completely free of reaction risk.

Common SCIT Side Effects

The most common reactions occur near the injection site and may include:

• Redness
• Itching
• Tenderness
• Swelling

Less commonly, a systemic reaction may cause hives, nasal symptoms, coughing, wheezing, throat swelling, dizziness, or anaphylaxis. This is why SCIT must be administered with observation and emergency preparedness.

Common SLIT Side Effects

SLIT reactions are usually localized to the mouth or throat and may include:

• Oral itching or tingling
• Mild lip or tongue swelling
• Throat irritation
• Ear itching
• Temporary stomach discomfort

Severe systemic reactions are less common with SLIT than with SCIT, but they remain possible. FDA-approved SLIT tablets carry boxed warnings regarding potentially serious allergic reactions. Patients may be prescribed epinephrine and instructed on when and how to use it.

Uncontrolled or severe asthma may increase the risk associated with allergen immunotherapy. A clinician should evaluate asthma control before treatment begins and throughout the program.

7. Convenience

SLIT usually requires fewer clinic visits and no injections. This may make it preferable for patients with:

• Needle anxiety
• Limited transportation
• Demanding work schedules
• Long travel distances to an allergy clinic
• Difficulty attending frequent build-up appointments

SCIT may be more convenient for patients who prefer scheduled medical supervision rather than remembering a daily home treatment.

Convenience should be evaluated over the full treatment period. A daily therapy is only convenient when the patient can take it consistently.

8. Cost and Insurance Coverage

The total cost of immunotherapy depends on:

• The specific product or formulation
• Office-visit charges
• Allergy testing
• Insurance coverage
• Pharmacy benefits
• Treatment duration
• Copayments and deductibles
• Travel and time away from work

SCIT is commonly covered by insurance when medically indicated, although injection and office-visit expenses may apply.

FDA-approved SLIT tablets may be covered through a prescription-drug benefit. Customized liquid SLIT drops are often not covered because they are not FDA-approved products, although policies vary considerably.

Patients should ask both the prescriber and insurer for an estimate before selecting a treatment route.

Is SCIT or SLIT Better for Multiple Allergies?

SCIT is often considered when a patient has several clinically relevant environmental allergies because a physician may be able to address multiple compatible allergens in a customized injection program.

An FDA-approved SLIT tablet generally treats one defined allergen or allergen group. A person taking a grass tablet, for example, should not assume that it will also treat symptoms caused by dust mites, pets, mold, or ragweed.

Customized liquid drops may contain more than one allergen, but formulation, concentration, evidence, and prescribing practices vary. The clinician must determine whether the allergens identified on testing are actually responsible for the patient’s symptoms and whether they can be appropriately included in the selected treatment.

More allergens do not necessarily produce a better formulation. Treatment should focus on allergens that are both clinically relevant and supported by the chosen immunotherapy approach.

Who May Be a Candidate for Allergy Immunotherapy?

A clinician may consider SCIT or SLIT when:

• Allergy symptoms are confirmed by history and appropriate testing.
• Avoiding the allergen is difficult or unrealistic.
• Antihistamines, nasal sprays, or other medications do not provide adequate control.
• Medications cause unacceptable side effects.
• The patient wants to reduce long-term dependence on symptom-relief medication.
• Allergies substantially interfere with sleep, work, school, exercise, or daily activities.
• The patient understands the risks, benefits, and long-term commitment.

A positive skin or blood test alone does not automatically mean that immunotherapy is needed. The test result must match the patient’s actual symptoms and exposure pattern.

Who May Not Be a Good Candidate?

Immunotherapy may need to be avoided, postponed, or modified in patients with certain conditions. Important considerations include:

• Poorly controlled asthma
• Previous severe reactions to immunotherapy
• Inability to recognize or report a serious reaction
• Inability to follow the treatment schedule
• Certain cardiovascular conditions
• Use of medications that may complicate treatment of anaphylaxis
• Pregnancy at the time a new build-up program would begin
• Eosinophilic esophagitis, particularly when considering SLIT tablets
• Active mouth sores, significant oral inflammation, or recent oral surgery when using SLIT

These factors do not always produce an automatic exclusion. They require individualized evaluation by a qualified clinician.

How Long Do SCIT and SLIT Take to Work?

Allergen immunotherapy is not an immediate-relief treatment.

Some patients notice improvement during the build-up period or within the first several months. Others may require a year at an effective maintenance dose before the benefit can be properly evaluated.

Treatment commonly continues for several years. Stopping too early may limit the opportunity to achieve sustained improvement. At the same time, therapy should be reassessed when symptoms do not improve despite an adequate dose, duration, adherence, and confirmation of the relevant allergens.

Patients should continue prescribed rescue or controller medications unless their clinician advises otherwise.

Can You Switch From SCIT to SLIT?

Switching may be possible, but the two treatments are not dose-for-dose equivalents.

A patient may consider changing routes because of:

• Injection reactions
• Needle anxiety
• Difficulty attending clinic appointments
• Relocation
• Changes in insurance coverage
• Poor adherence
• Availability of an appropriate SLIT tablet
• A change in the clinically relevant allergens

The prescriber must review the allergen targets, previous dose, treatment interruptions, asthma status, reaction history, and the evidence supporting the proposed SLIT product or formulation. Patients should never convert an injection dose into a home drop dose on their own.